201 related articles for article (PubMed ID: 17999742)
1. Targeting stromal cells for the treatment of platelet-derived growth factor C-induced hepatocellular carcinogenesis.
Campbell JS; Johnson MM; Bauer RL; Hudkins KL; Gilbertson DG; Riehle KJ; Yeh MM; Alpers CE; Fausto N
Differentiation; 2007 Nov; 75(9):843-52. PubMed ID: 17999742
[TBL] [Abstract][Full Text] [Related]
2. C-kit inhibition by imatinib mesylate attenuates progenitor cell expansion and inhibits liver tumor formation in mice.
Knight B; Tirnitz-Parker JE; Olynyk JK
Gastroenterology; 2008 Sep; 135(3):969-79, 979.e1. PubMed ID: 18602920
[TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.
Basciani S; Brama M; Mariani S; De Luca G; Arizzi M; Vesci L; Pisano C; Dolci S; Spera G; Gnessi L
Cancer Res; 2005 Mar; 65(5):1897-903. PubMed ID: 15753388
[TBL] [Abstract][Full Text] [Related]
4. Kit and PDGFR-alpha activities are necessary for Notch4/Int3-induced tumorigenesis.
Raafat A; Zoltan-Jones A; Strizzi L; Bargo S; Kimura K; Salomon D; Callahan R
Oncogene; 2007 Feb; 26(5):662-72. PubMed ID: 16878155
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of platelet-derived growth factor receptor alpha in endothelial cells of hepatocellular carcinoma associated with high metastatic potential.
Zhang T; Sun HC; Xu Y; Zhang KZ; Wang L; Qin LX; Wu WZ; Liu YK; Ye SL; Tang ZY
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8557-63. PubMed ID: 16361537
[TBL] [Abstract][Full Text] [Related]
6. Progesterone sensitizes breast cancer MCF7 cells to imatinib inhibitory effects.
Rocha A; Azevedo I; Soares R
J Cell Biochem; 2008 Feb; 103(2):607-14. PubMed ID: 17614352
[TBL] [Abstract][Full Text] [Related]
7. Synergistic effects of imatinib and carboplatin on VEGF, PDGF and PDGF-Rα/ß expression in squamous cell carcinoma of the head and neck in vitro.
Schultz JD; Rotunno S; Riedel F; Anders C; Erben P; Hofheinz RD; Faber A; Thorn C; Sommer JU; Hörmann K; Sauter A
Int J Oncol; 2011 Apr; 38(4):1001-12. PubMed ID: 21249316
[TBL] [Abstract][Full Text] [Related]
8. Imatinib mesylate inhibits proliferation and modulates cytokine expression of human cancer-associated stromal fibroblasts from colorectal metastases.
Mueller L; Goumas FA; Himpel S; Brilloff S; Rogiers X; Broering DC
Cancer Lett; 2007 Jun; 250(2):329-38. PubMed ID: 17141949
[TBL] [Abstract][Full Text] [Related]
9. Human glioblastoma and carcinoma xenograft tumors treated by combined radiation and imatinib (Gleevec).
Oertel S; Krempien R; Lindel K; Zabel A; Milker-Zabel S; Bischof M; Lipson KE; Peschke P; Debus J; Abdollahi A; Huber PE
Strahlenther Onkol; 2006 Jul; 182(7):400-7. PubMed ID: 16826359
[TBL] [Abstract][Full Text] [Related]
10. Imatinib mesylate attenuates fibrosis in coxsackievirus b3-induced chronic myocarditis.
Leipner C; Grün K; Müller A; Buchdunger E; Borsi L; Kosmehl H; Berndt A; Janik T; Uecker A; Kiehntopf M; Böhmer FD
Cardiovasc Res; 2008 Jul; 79(1):118-26. PubMed ID: 18326555
[TBL] [Abstract][Full Text] [Related]
11. A crucial function of PDGF in TGF-beta-mediated cancer progression of hepatocytes.
Gotzmann J; Fischer AN; Zojer M; Mikula M; Proell V; Huber H; Jechlinger M; Waerner T; Weith A; Beug H; Mikulits W
Oncogene; 2006 May; 25(22):3170-85. PubMed ID: 16607286
[TBL] [Abstract][Full Text] [Related]
12. CD117 (c-kit) expression in human hepatocellular carcinoma.
Becker G; Schmitt-Graeff A; Ertelt V; Blum HE; Allgaier HP
Clin Oncol (R Coll Radiol); 2007 Apr; 19(3):204-8. PubMed ID: 17359908
[TBL] [Abstract][Full Text] [Related]
13. Imatinib mesylate inhibits the proliferation-stimulating effect of human lung cancer-associated stromal fibroblasts on lung cancer cells.
Kinoshita K; Nakagawa K; Hamada J; Hida Y; Tada M; Kondo S; Moriuchi T
Int J Oncol; 2010 Oct; 37(4):869-77. PubMed ID: 20811709
[TBL] [Abstract][Full Text] [Related]
14. Platelet-derived growth factor receptors: a therapeutic target in solid tumors.
George D
Semin Oncol; 2001 Oct; 28(5 Suppl 17):27-33. PubMed ID: 11740804
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of imatinib in unresectable hepatocellular carcinoma.
Lin AY; Fisher GA; So S; Tang C; Levitt L
Am J Clin Oncol; 2008 Feb; 31(1):84-8. PubMed ID: 18376233
[TBL] [Abstract][Full Text] [Related]
16. Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity.
Holtkamp N; Okuducu AF; Mucha J; Afanasieva A; Hartmann C; Atallah I; Estevez-Schwarz L; Mawrin C; Friedrich RE; Mautner VF; von Deimling A
Carcinogenesis; 2006 Mar; 27(3):664-71. PubMed ID: 16357008
[TBL] [Abstract][Full Text] [Related]
17. Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo.
Irsan I; Akisue T; Hara H; Fujimoto T; Imabori M; Doita M; Kuroda R; Fujioka H; Kawamoto T; Yamamoto T; Kurosaka M
Anticancer Res; 2007; 27(1A):423-9. PubMed ID: 17352263
[TBL] [Abstract][Full Text] [Related]
18. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.
Buchdunger E; Cioffi CL; Law N; Stover D; Ohno-Jones S; Druker BJ; Lydon NB
J Pharmacol Exp Ther; 2000 Oct; 295(1):139-45. PubMed ID: 10991971
[TBL] [Abstract][Full Text] [Related]
19. Leptin induces proliferation and anti-apoptosis in human hepatocarcinoma cells by up-regulating cyclin D1 and down-regulating Bax via a Janus kinase 2-linked pathway.
Chen C; Chang YC; Liu CL; Liu TP; Chang KJ; Guo IC
Endocr Relat Cancer; 2007 Jun; 14(2):513-29. PubMed ID: 17639064
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]